James Condulis
Stock Analyst at Stifel
(2.22)
# 3,670
Out of 5,182 analysts
12
Total ratings
50%
Success rate
1.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by James Condulis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TECX Tectonic Therapeutic | Initiates: Buy | $75 | $28.47 | +163.44% | 1 | Apr 14, 2026 | |
| AMLX Amylyx Pharmaceuticals | Initiates: Buy | $21 | $16.96 | +23.82% | 1 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Hold | $24 → $6 | $5.49 | +9.29% | 2 | Mar 2, 2026 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $44 → $50 | $30.53 | +63.77% | 2 | Dec 16, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $7.5 → $10 | $4.21 | +137.53% | 1 | Dec 5, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $87 → $96 | $61.54 | +56.00% | 2 | Sep 2, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $74 → $108 | $52.76 | +104.70% | 2 | Mar 28, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Hold | $30 | $30.66 | -2.15% | 1 | Jan 22, 2025 |
Tectonic Therapeutic
Apr 14, 2026
Initiates: Buy
Price Target: $75
Current: $28.47
Upside: +163.44%
Amylyx Pharmaceuticals
Mar 3, 2026
Initiates: Buy
Price Target: $21
Current: $16.96
Upside: +23.82%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Hold
Price Target: $24 → $6
Current: $5.49
Upside: +9.29%
NewAmsterdam Pharma Company
Dec 16, 2025
Maintains: Buy
Price Target: $44 → $50
Current: $30.53
Upside: +63.77%
X4 Pharmaceuticals
Dec 5, 2025
Maintains: Buy
Price Target: $7.5 → $10
Current: $4.21
Upside: +137.53%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $87 → $96
Current: $61.54
Upside: +56.00%
Soleno Therapeutics
Mar 28, 2025
Maintains: Buy
Price Target: $74 → $108
Current: $52.76
Upside: +104.70%
Edgewise Therapeutics
Jan 22, 2025
Initiates: Hold
Price Target: $30
Current: $30.66
Upside: -2.15%